대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Serum endocan level and prognosis of IgA nephropathy
저자	Yu Ho Lee*, Ju-Young Moon, Kyung-Hwan Jeong, Se-Yun Kim, Yang Gyun Kim, Tae Won Lee, Chun-Gyoo Ihm, Sang-Ho Lee
출판정보	2016; 2016(1):
키워드	endocan, endothelial cell-specific molecule-1, IgA nephropathy
초록	Background: Endocan, previously called endothelial cell-specific molecule-1, is a soluble proteoglycan that is secreted from vascular endothelial cells. Elevated plasma endocan levels were shown to be associated with poor cardiovascular outcomes in patients with chronic kidney disease. We investigated the clinical relevance of plasma and urine endocan levels in patients with IgA nephropathy (IgAN). Methods: Sixty-four patients with IgAN and twenty healthy controls were enrolled in this study. Plasma and urine endocan levels were measured. Clinical parameters, pathologic grades and renal outcomes were compared among subgroups with different plasma and urine endocan levels. Results: Plasma endocan levels were similar in patients with IgAN and controls (99.2 [interquartile range (IQR) 54.5-150.8] vs. 117.9 [IQR 56.6-158.9] pg/mL, p=0.571). In contrast, urine endocan levels were significantly higher in patients with IgAN than in controls (182.6 [IQR 1.5-909.3] vs. 0 [IQR 0-24.2] pg/gCr, p<0.001). Patients with high plasma endocan levels (4th quartile) showed high serum CRP, severe proteinuria, and rapid decline in renal function. Both plasma and urine endocan levels were higher in patients with advanced pathologic grades. Urine endocan levels were elevated in patients with poor renal function, but the levels were not significantly associated to renal outcome. Cox proportional hazard models showed that high plasma endocan was an independent risk factor for CKD progression after adjusting for the well-known predictors of outcome in patients with IgAN. Conclusion: This study suggested that plasma endocan showed potential as a prognostic factor in patients with IgAN.
원문(PDF)	PDF 원문보기

목록

위로가기